Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020
- Author:
Hye-Kyung JUNG
1
;
Seung Joo KANG
;
Yong Chan LEE
;
Hyo-Joon YANG
;
Seon-Young PARK
;
Cheol Min SHIN
;
Sung Eun KIM
;
Hyun Chul LIM
;
Jie-Hyun KIM
;
Su Youn NAM
;
Woon Geon SHIN
;
Jae Myung PARK
;
Il Ju CHOI
;
Jae Gyu KIM
;
Miyoung CHOI
;
Author Information
- Publication Type:14
- From:The Korean Journal of Internal Medicine 2021;36(4):807-838
- CountryRepublic of Korea
- Language:English
- Abstract: Helicobacter pylori infection is one of the most common infectious diseases worldwide. H. pylori is responsible for substantial gastrointestinal morbidity with a high disease burden. Since the revision of the H. pylori Clinical Practice Guidelines in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a clarithromycin based triple therapy. According to a nationwide randomized controlled study by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due to increased antimicrobial resistance to clarithromycin. The clinical practice guidelines for treatment of H. pylori were updated based on evidence-based medicine from a meta-analysis conducted on a target group receiving the latest level of eradication therapy. The draft recommendations developed based on the meta-analysis were finalized after expert consensus on three recommendations regarding the indication for treatment and eight recommendations on the treatment itself. These guidelines were designed to provide clinical evidence for the treatment of H. pylori to patients, nurses, medical school students, policymakers, and clinicians. These may differ from current medical insurance standards, and will be revised if more evidence emerges in the future.
